Immune  ||| S:0 E:7 ||| JJ
checkpoint  ||| S:7 E:18 ||| JJ
blockade  ||| S:18 E:27 ||| NN
as  ||| S:27 E:30 ||| IN
a  ||| S:30 E:32 ||| DT
novel  ||| S:32 E:38 ||| NN
immunotherapeutic  ||| S:38 E:56 ||| NN
strategy  ||| S:56 E:65 ||| NN
for  ||| S:65 E:69 ||| IN
renal  ||| S:69 E:75 ||| JJ
cell  ||| S:75 E:80 ||| NN
carcinoma ||| S:80 E:89 ||| NNS
:  ||| S:89 E:91 ||| :
a  ||| S:91 E:93 ||| DT
review  ||| S:93 E:100 ||| NN
of  ||| S:100 E:103 ||| IN
clinical  ||| S:103 E:112 ||| JJ
trials  ||| S:112 E:119 ||| NNS
Renal  ||| S:119 E:125 ||| JJ
cell  ||| S:125 E:130 ||| NN
carcinoma  ||| S:130 E:140 ||| NNS
( ||| S:140 E:141 ||| -LRB-
RCC ||| S:141 E:144 ||| NNP
)  ||| S:144 E:146 ||| -RRB-
is  ||| S:146 E:149 ||| VBZ
a  ||| S:149 E:151 ||| DT
common  ||| S:151 E:158 ||| JJ
genitourinary  ||| S:158 E:172 ||| JJ
malignancy ||| S:172 E:182 ||| NN
;  ||| S:182 E:184 ||| :
when  ||| S:184 E:189 ||| WRB
metastatic ||| S:189 E:199 ||| NNS
,  ||| S:199 E:201 ||| ,
it  ||| S:201 E:204 ||| PRP
is  ||| S:204 E:207 ||| VBZ
almost  ||| S:207 E:214 ||| RB
uniformly  ||| S:214 E:224 ||| RB
fatal ||| S:224 E:229 ||| JJ
.  ||| S:229 E:231 ||| .
For  ||| S:231 E:235 ||| IN
many  ||| S:235 E:240 ||| JJ
years  ||| S:240 E:246 ||| NNS
non-specific  ||| S:246 E:259 ||| JJ
immunotherapy  ||| S:259 E:273 ||| NN
was  ||| S:273 E:277 ||| VBD
the  ||| S:277 E:281 ||| DT
mainstay  ||| S:281 E:290 ||| NN
of  ||| S:290 E:293 ||| IN
treatment  ||| S:293 E:303 ||| NN
for  ||| S:303 E:307 ||| IN
metastatic  ||| S:307 E:318 ||| JJ
RCC ||| S:318 E:321 ||| NNP
,  ||| S:321 E:323 ||| ,
but  ||| S:323 E:327 ||| CC
led  ||| S:327 E:331 ||| VBN
to  ||| S:331 E:334 ||| TO
only  ||| S:334 E:339 ||| RB
modest  ||| S:339 E:346 ||| JJ
success  ||| S:346 E:354 ||| NN
and  ||| S:354 E:358 ||| CC
significant  ||| S:358 E:370 ||| JJ
side-effects ||| S:370 E:382 ||| NN
.  ||| S:382 E:384 ||| .
More  ||| S:384 E:389 ||| RBR
recently ||| S:389 E:397 ||| RB
,  ||| S:397 E:399 ||| ,
seven  ||| S:399 E:405 ||| CD
targeted  ||| S:405 E:414 ||| JJ
therapy  ||| S:414 E:422 ||| NN
drugs  ||| S:422 E:428 ||| NNS
have  ||| S:428 E:433 ||| VBP
been  ||| S:433 E:438 ||| VBN
approved  ||| S:438 E:447 ||| VBN
to  ||| S:447 E:450 ||| TO
treat  ||| S:450 E:456 ||| VB
metastatic  ||| S:456 E:467 ||| JJ
RCC ||| S:467 E:470 ||| NNP
;  ||| S:470 E:472 ||| :
these  ||| S:472 E:478 ||| DT
drugs  ||| S:478 E:484 ||| NNS
impede  ||| S:484 E:491 ||| VBP
RCC  ||| S:491 E:495 ||| JJ
cell  ||| S:495 E:500 ||| NN
growth ||| S:500 E:506 ||| NN
,  ||| S:506 E:508 ||| ,
proliferation ||| S:508 E:521 ||| NN
,  ||| S:521 E:523 ||| ,
and  ||| S:523 E:527 ||| CC
angiogenesis  ||| S:527 E:540 ||| NNS
and  ||| S:540 E:544 ||| CC
have  ||| S:544 E:549 ||| VBP
had  ||| S:549 E:553 ||| VBN
a  ||| S:553 E:555 ||| DT
significant  ||| S:555 E:567 ||| JJ
impact  ||| S:567 E:574 ||| NN
on  ||| S:574 E:577 ||| IN
patient  ||| S:577 E:585 ||| JJ
outcomes ||| S:585 E:593 ||| NNS
,  ||| S:593 E:595 ||| ,
but  ||| S:595 E:599 ||| CC
with  ||| S:599 E:604 ||| IN
infrequent  ||| S:604 E:615 ||| JJ
long  ||| S:615 E:620 ||| JJ
term  ||| S:620 E:625 ||| NN
responders ||| S:625 E:635 ||| NN
.  ||| S:635 E:637 ||| .
Thus ||| S:637 E:641 ||| RB
,  ||| S:641 E:643 ||| ,
a  ||| S:643 E:645 ||| DT
renewed  ||| S:645 E:653 ||| JJ
emphasis  ||| S:653 E:662 ||| NN
on  ||| S:662 E:665 ||| IN
immunotherapy  ||| S:665 E:679 ||| NN
has  ||| S:679 E:683 ||| VBZ
emerged  ||| S:683 E:691 ||| VBN
over  ||| S:691 E:696 ||| IN
the  ||| S:696 E:700 ||| DT
last  ||| S:700 E:705 ||| JJ
several  ||| S:705 E:713 ||| JJ
years  ||| S:713 E:719 ||| NNS
with  ||| S:719 E:724 ||| IN
the  ||| S:724 E:728 ||| DT
development  ||| S:728 E:740 ||| NN
and  ||| S:740 E:744 ||| CC
testing  ||| S:744 E:752 ||| NN
of  ||| S:752 E:755 ||| IN
a  ||| S:755 E:757 ||| DT
novel  ||| S:757 E:763 ||| NN
class  ||| S:763 E:769 ||| NN
of  ||| S:769 E:772 ||| IN
immunotherapeutic  ||| S:772 E:790 ||| JJ
agents  ||| S:790 E:797 ||| NNS
called  ||| S:797 E:804 ||| VBD
checkpoint  ||| S:804 E:815 ||| JJ
inhibitors ||| S:815 E:825 ||| NN
.  ||| S:825 E:827 ||| .
These  ||| S:827 E:833 ||| DT
drugs  ||| S:833 E:839 ||| NNS
have  ||| S:839 E:844 ||| VBP
targeted  ||| S:844 E:853 ||| VBN
the  ||| S:853 E:857 ||| DT
programmed  ||| S:857 E:868 ||| JJ
cell  ||| S:868 E:873 ||| NN
death  ||| S:873 E:879 ||| NN
1  ||| S:879 E:881 ||| CD
( ||| S:881 E:882 ||| -LRB-
PD-1 ||| S:882 E:886 ||| NNP
)  ||| S:886 E:888 ||| -RRB-
and  ||| S:888 E:892 ||| CC
cytotoxic  ||| S:892 E:902 ||| JJ
leukocyte  ||| S:902 E:912 ||| NN
antigen  ||| S:912 E:920 ||| VBD
4  ||| S:920 E:922 ||| CD
( ||| S:922 E:923 ||| -LRB-
CTLA-4 ||| S:923 E:929 ||| NNP
)  ||| S:929 E:931 ||| -RRB-
pathways  ||| S:931 E:940 ||| NN
on  ||| S:940 E:943 ||| IN
regulatory  ||| S:943 E:954 ||| JJ
T  ||| S:954 E:956 ||| NN
cells ||| S:956 E:961 ||| NNS
,  ||| S:961 E:963 ||| ,
leading  ||| S:963 E:971 ||| VBG
to  ||| S:971 E:974 ||| TO
immune  ||| S:974 E:981 ||| JJ
response  ||| S:981 E:990 ||| NN
enhancement  ||| S:990 E:1002 ||| NN
and  ||| S:1002 E:1006 ||| CC
immune-mediated  ||| S:1006 E:1022 ||| JJ
anti-tumor  ||| S:1022 E:1033 ||| JJ
effects  ||| S:1033 E:1041 ||| NNS
in  ||| S:1041 E:1044 ||| IN
multiple  ||| S:1044 E:1053 ||| JJ
malignancies ||| S:1053 E:1065 ||| NN
,  ||| S:1065 E:1067 ||| ,
including  ||| S:1067 E:1077 ||| VBG
RCC ||| S:1077 E:1080 ||| NNP
.  ||| S:1080 E:1082 ||| .
A  ||| S:1082 E:1084 ||| DT
number  ||| S:1084 E:1091 ||| NN
of  ||| S:1091 E:1094 ||| IN
studies  ||| S:1094 E:1102 ||| NNS
recently  ||| S:1102 E:1111 ||| RB
reported  ||| S:1111 E:1120 ||| VBD
utilizing  ||| S:1120 E:1130 ||| JJ
checkpoint  ||| S:1130 E:1141 ||| JJ
inhibitors ||| S:1141 E:1151 ||| NN
,  ||| S:1151 E:1153 ||| ,
either  ||| S:1153 E:1160 ||| CC
alone  ||| S:1160 E:1166 ||| RB
or  ||| S:1166 E:1169 ||| CC
in  ||| S:1169 E:1172 ||| IN
combination  ||| S:1172 E:1184 ||| NN
with  ||| S:1184 E:1189 ||| IN
other  ||| S:1189 E:1195 ||| JJ
checkpoint  ||| S:1195 E:1206 ||| JJ
inhibitors  ||| S:1206 E:1217 ||| NN
or  ||| S:1217 E:1220 ||| CC
vascular  ||| S:1220 E:1229 ||| JJ
endothelial  ||| S:1229 E:1241 ||| JJ
growth  ||| S:1241 E:1248 ||| NN
factor  ||| S:1248 E:1255 ||| NN
targeting  ||| S:1255 E:1265 ||| VBG
agents ||| S:1265 E:1271 ||| NNS
,  ||| S:1271 E:1273 ||| ,
and  ||| S:1273 E:1277 ||| CC
these  ||| S:1277 E:1283 ||| DT
studies  ||| S:1283 E:1291 ||| NNS
have  ||| S:1291 E:1296 ||| VBP
shown  ||| S:1296 E:1302 ||| VBN
significant  ||| S:1302 E:1314 ||| JJ
and  ||| S:1314 E:1318 ||| CC
at  ||| S:1318 E:1321 ||| IN
times  ||| S:1321 E:1327 ||| NNS
durable  ||| S:1327 E:1335 ||| JJ
responses  ||| S:1335 E:1345 ||| NNS
in  ||| S:1345 E:1348 ||| IN
RCC  ||| S:1348 E:1352 ||| NNP
patients ||| S:1352 E:1360 ||| NNS
.  ||| S:1360 E:1362 ||| .
This  ||| S:1362 E:1367 ||| DT
has  ||| S:1367 E:1371 ||| VBZ
led  ||| S:1371 E:1375 ||| VBN
to  ||| S:1375 E:1378 ||| TO
the  ||| S:1378 E:1382 ||| DT
development  ||| S:1382 E:1394 ||| NN
of  ||| S:1394 E:1397 ||| IN
further  ||| S:1397 E:1405 ||| JJ
phase  ||| S:1405 E:1411 ||| NN
I ||| S:1411 E:1412 ||| PRP
,  ||| S:1412 E:1414 ||| ,
II ||| S:1414 E:1416 ||| NNP
,  ||| S:1416 E:1418 ||| ,
and  ||| S:1418 E:1422 ||| CC
III  ||| S:1422 E:1426 ||| NNP
trials  ||| S:1426 E:1433 ||| NNS
and  ||| S:1433 E:1437 ||| CC
this  ||| S:1437 E:1442 ||| DT
review  ||| S:1442 E:1449 ||| NN
will  ||| S:1449 E:1454 ||| MD
discuss  ||| S:1454 E:1462 ||| VB
the  ||| S:1462 E:1466 ||| DT
history  ||| S:1466 E:1474 ||| NN
and  ||| S:1474 E:1478 ||| CC
currently  ||| S:1478 E:1488 ||| RB
available  ||| S:1488 E:1498 ||| JJ
data  ||| S:1498 E:1503 ||| NNS
for  ||| S:1503 E:1507 ||| IN
immune  ||| S:1507 E:1514 ||| JJ
checkpoint  ||| S:1514 E:1525 ||| JJ
blockade  ||| S:1525 E:1534 ||| NN
in  ||| S:1534 E:1537 ||| IN
RCC ||| S:1537 E:1540 ||| NNP
.  ||| S:1540 E:1542 ||| .
